Genentech: FDA Approves Tecentriq as Adjuvant Treatment for Certain Lung Cancer Patients
October 15 2021 - 01:20PM
Dow Jones News
By Stephen Nakrosis
Genentech on Friday said the Food and Drug Administration
approved its Tencentriq as an adjuvant treatment for certain lung
cancer patients.
The company said Tencentriq, or atezolizumab, was approved as
adjuvant treatment following surgery and platinum-based
chemotherapy for certain adults with Stage II-IIIA non-small cell
lung cancer.
Genentech said Tecentriq is the first and only cancer
immunotherapy available for adjuvant treatment of NSCLC.
The company said the approval was based on results from interim
analysis of the Phase III IMpower010 study, which showed treatment
with Tecentriq improved disease-free survival by over one-third in
PD-L1-positive Stage II-IIIA lung cancer, compared with the best
supportive care.
Genentech is a member of the Roche Group.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 15, 2021 13:05 ET (17:05 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2023 to Mar 2024